2020 年第 4 期 第 15 卷

氨氯地平贝那普利片（Ⅱ）治疗原发性高血压的临床效果和依从性及经济性分析

Efficacy, compliance and economics of amlodipine besylate and benazepril hydrochloride tablets Ⅱ in treatment of essential hypertension

作者：吴小英阴彦斌陈岩戴文鑫

英文作者：Wu Xiaoying Yin Yanbin Chen Yan Dai Wenxin

单位：海南省人民医院医疗保健中心，海口570311

英文单位：Health Care Center Hainan General Hospital Haikou 570311 China

关键词：原发性高血压；氨氯地平贝那普利片（Ⅱ）；疗效；依从性；经济性

英文关键词：Essentialhypertension;Amlodipinebesylateandbenazeprilhydrochloridetablets(Ⅱ);Efficacy;Compliance;Economicalefficiency

• 摘要：

• 【摘要】目的    评估氨氯地平贝那普利片（Ⅱ）治疗原发性轻中度高血压患者的临床效果、依从性及经济性。方法    选取2016年1月至2018年12月海南省人民医院收治的原发性高血压患者100例，完全随机分为单片复方制剂（SPC）组和联合用药组，各50例。SPC组服用氨氯地平贝那普利片（Ⅱ）治疗，联合用药组服用氨氯地平片＋贝那普利片治疗，均治疗12周。通过对2组患者定期随访，了解患者血压达标情况、用药依从性情况及不良反应等，并对总体疗效及用药花费进行比较。结果    SPC组和联合用药组的总有效率比较［96.0%（48/50）比94.0%（47/50）］，差异无统计学意义（P＝0.646）。治疗后SPC组和联合用药组坐位收缩压和舒张压均较治疗前明显降低［收缩压：（133±14）mmHg（1 mmHg=0.133 kPa）比（150±13）mmHg、（128±11）mmHg比（150±12）mmHg；舒张压：（87±8）mmHg比（100±5）mmHg、（83±6）mmHg比（99±3）mmHg］（均P＜0.05），2组间比较差异无统计学意义（均P＞0.05）。2组不良反应发生率差异无统计学意义（P＝0.749）。SPC组依从性明显优于联合用药组［94.0%（47/50）比82.0%（41/50）］，差异有统计学意义（P=0.037）。同一时间段SPC总费用为15 298.50元，较联合用药（26 933.08元）降低了43.2%。结论    氨氯地平贝那普利片（Ⅱ）复方制剂和氨氯地平片＋贝那普利片联合治疗原发性高血压均效果明显，均无明显不良反应。SPC可以优化血压管理，明显改善治疗依从性，降低药物成本。

• 【Abstract】Objective    To evaluate the efficacy, compliance and economics of amlodipine besylate and benazepril hydrochloride tablets (Ⅱ)  in treatment of primary mild to moderate hypertension. Methods    A total of 100 patients with primary mild to moderate hypertension admitted to Hainan General Hospital from January 2016 to December 2018 were randomly assigned to have single pill combination(SPC) using amlodipine besylate and benazepril hydrochloride tablets (Ⅱ) and amlodipine tablets plus benazepril tablets for 12 weeks. Blood pressure control, patient compliance, adverse reactions, overall efficacy and drug expense were analyzed. Results    The total effective rate was similar between SPC and two drugs combination［96.0%（48/50） vs 94.0%（47/50）］（P＝0.646）. Sitting systolic pressure and diastolic pressure significantly decreased after both treatments［systolic pressure： （133±14）mmHg vs （150±13）mmHg, （128±11）mmHg vs （150±12）mmHg； diastolic pressure：（87±8）mmHg vs （100±5）mmHg, （83±6）mmHg vs （99±3）mmHg］（all P＜0.05）, but no statistical difference was observed between the two group（P＞0.05）. There was no significant difference in adverse reaction rate between the two treatments(P＝0.749). The compliance rate with SPC was significantly higher than that with two drugs combination［94.0%（47/50） vs 82.0%（41/50）］（P=0.037）. The total expense of SPC was 15 298.50 yuan, which was reduced by 43.2% compared with the expense of drug combination（26 933.08 yuan）. Conclusions    Amlodipine besylate and benazepril hydrochloride tablets (Ⅱ) show equal efficacy compared with the combination of amlodipine tablets plus benazepril tablets, and no obvious adverse reactions are observed. SPC shows advantages in optimizing blood pressure management, improving compliance and reducing medical cost.